[1] Nagore E, Insa A, Sanmartin O.Antineoplastic therapyinduced palmar plantar erythrodysesthesia ('hand-foot') syndrome.incidence, recognition and management[J]. Am J Clin Dermatol, 2000, 1(4):225-234.
[2] Zuehlke RK.Erythematous eruption of the palms and soles associated with mitotane therapy [J].Dermatologica, 1974, 148(2):90-92.
[3] Wilkes GM, Doyle D.Palmar-plantar erythrodysesthesia [J].J Oncol Pharm Practice, 2003, 9(4):137-150.
[4] Hellier I, Bessis D, Sotto A, et al.High-dose methotrexate-induced bullous variant of acral erythema[J].Arch Dermatol, 1996, 132(5):590-591.
[5] Blum JL, Jones SE, Buzdar AU, et al.Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer[J].J Clin Oncol, 1999, 17(2):485-493.
[6] Lorusso D, Stefano A Di, Carone V, et al.Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (hand-foot syndrome)[J].Ann Onc, 2007, 18(7):1159-1164.
[7] Tardi PG, Boman NL, Cullis PR.Liposomal Doxorubicin [J].J Drug Target, 1996, 4(3):129-140.
[8] Gordon KB, Tajuddin A, Guitart J, et al.Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy[J].Cancer, 1995, 75(8):2169-2173.
[9] Muggia FM, Hainsworth JD, Jeffers S, et al.Phase II study of liposomal doxorubicin in refractarory ovarian cancer:antitumor activity and toxicity modification by liposomal encapsulation[J].J Clin Oncol, 1997, 15(3):987-993.
[10] Uziely B, Jeffers S, Isacson R, et al.Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies[J].J Clin Oncol, 1995, 13 (7):1777-1785.
[11] Lyass O, Uziely B, Ben-Yosef R, et al.Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma[J].Cancer, 2000, 89(5):1037-1047.
[12] 陈新谦, 金有豫, 汤光.新编药物学[M].北京:人民卫生出版社, 2003:676.
[13] Douillard JY, Hoff PM, Skillings JR, et al.Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer[J].J Clin Oncol, 2002, 20(17):3605-3616.
[14] Milano G, Etienne-Grimaldi MC, Mari M, et al.Candidate mechanisms for capecitabine-related hand-foot syndrome[J].Br J Clin Pharmacol, 2008, 66(1):88-95.
[15] Toxicity of fluorouracil in patients with advanced colorectal cancer:effect of administration schedule and prognostic factors.Meta-Analysis Group In Cancer[J].J Clin Oncol, 1998, 16(11):3537-3541.
[16] Chiara S, Nobile MT, Barzacchi C.Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion[J].Eur J Cancer, 1997, 33(6):967-969.
[17] Kroll SS, Koller CA, Kaled S, et al.Chemotherapyinduced acral erythema:desquaminating lesions involving hands and feet[J].Ann Plast Surg, 1989, 23(3):263-265.
[18] Mangili G, Petrone M, Gentile C, et al.Prevention strategies in palmar-plantar erythrodysesthesia onset:the role of regional cooling[J].Gynecol Oncol, 2008, 108(2):332-335.
[19] Fabian CJ, Molina R, Slavik M, et al.Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continous 5-fluorouracil infusion [J].Invest New Drugs, 1990, 8(1):57-63.
[20] Vail DM, Chun R, Tham DH, et al.Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth)liposomes:a randomized double-blind clinical trial using a canine model [J].Clin Cancer Res, 1998, 4(6):1567-1571.
[21] Eng C, Mauer AM, Fleming GF, et al.Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cicplatin in patients with advanced solid tumors[J].Ann Oncol, 2001, 12(12):1743-1747.
[22] Drake RD, Lin WM, King M, et al.Oral dexamethasone attenuates Doxil(r)-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies [J].Gynecol Oncol, 2004, 94(2):320-324.
[23] Brown J, Burck K, Black D, et al.Treatment of cytarabine acral erythema with corticosteroids[J].J Am Acad Dermatol, 1991, 24(6Pt 1):1023-1025.
[24] Lopez A, Wallace L, Dorr R, et al.Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmarplantar erythrodysesthesia[J].Cancer Chemother Phamacol, 1999, 44(4):303-306.
[25] vonMoos R, Thuerlimann BJ, AaproM.Pegylated liposomal doxorubicin-associated hand-foot syndrome:recommendations of an international panel of experts[J].Eur J Cancer, 2008, 44(6):781-790.
[26] Solomon SD, McMurray JJ, Pfeffer MA, et al.Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention[J].N Engl J Med, 2005, 352(11):1071-1780. |
